तुलना करने के लिए मीट्रिक्स | 688222 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध688222पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 86.3x | 34.6x | −0.4x | |
PEG अनुपात | 1.33 | 0.32 | 0.00 | |
क़ीमत/बुक | 6.9x | 3.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 18.3x | 4.7x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 5.0% | 19.6% | 54.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 15.5% | 8.4% | अनलॉक करें |
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; HG153 a Menin-MLL tablet; HG248; HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation; and HGP1069, a ROCK2 inhibitor eye drop. In addition, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Further, the company focuses on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. The company was incorporated in 2012 and is based in Chengdu, China.